Dexmedetomine vs Dexamethasone in TAB Block for Abdominal Surgries

A

Ain Shams University

Status and phase

Active, not recruiting
Phase 4

Conditions

Anesthesia

Treatments

Drug: Dexmedetomidine

Study type

Interventional

Funder types

Other

Identifiers

NCT05323565
FMASU M D 184/2020

Details and patient eligibility

About

Randomized controlled clinical Trial to compare the efficacy and duration of postoperative analgesia achieved after adding dexmedetomidine or dexamethasone to bupivacaine in TAP block for lower open abdominal surgeries.

Full description

A Comparative study between the use of dexmedetomidine versus dexamethasone as adjuvant to bupivacaine in ultrasound-guided transversus abdominis plane block for post-operative pain relief in patients undergoing lower open abdominal surgeries

Enrollment

45 patients

Sex

All

Ages

20 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult patients, Age 20-60 years. Elective operation under general anesthesia. Physical Status: ASA I and II Patients. Body mass index 25-35 kg/m2.

Exclusion criteria

  • Infection at site of injection.
  • Patient refusal.
  • Psychiatric or physical illness that lead to inability to cooperate, speak or read.
  • Abdominal operations under spinal anesthesia.
  • History or evidence of coagulopathy.
  • Known allergies to drugs used .
  • Preexisting neurological disorders.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

45 participants in 3 patient groups

Group A (n=15): (Dexamethasone group)
Active Comparator group
Description:
Patients will receive 20 ml 0.25% bupivacaine plus 4 mg dexamethasone on each side TAB bock.
Treatment:
Drug: Dexmedetomidine
Group B (n=15): (Dexmedetomidine group)
Active Comparator group
Description:
Patients will receive 20 ml 0.25% bupivacaine plus 0.5 mcg/kg of dexmedetomidine on each side TAB block.
Treatment:
Drug: Dexmedetomidine
Group C (n=15): (control group)
Sham Comparator group
Description:
Patients will receive 20 ml 0.25% bupivacaine on each side TAB block.
Treatment:
Drug: Dexmedetomidine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems